Drug Type Small molecule drug |
Synonyms- |
Mechanism EGFR L861Q mutation antagonists, EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Preclinical | TH | 01 Nov 2024 |